REFRACTIVE OUTCOMES OF SMILE PRO FOR MYOPIA AND MYOPIC ASTIGMATISM.
Published 2025 - 29th ESCRS Winter Meeting
Reference: PO044 | Type: Free Paper | DOI: 10.82333/s9zf-sd92
Authors: Alexandros John Kanellopoulos 1 , Anastasios John Kanellopoulos* 2 , Despoina Karadimou 1 , Stellia Georgiadou 1
1Ophthalmology,Laservision Ambulatory Eye Surgery Unit,Athens,Greece, 2Ophthalmology,Laservision Ambulatory Eye Surgery Unit,Athens,Greece;Ophthalmology,NYU Med School,New York,United States
Purpose
To evaluate the safety and efficacy of myopia correction treatments with SMILE-pro.
Setting
The Laservision.gr Clinical and Research Institute, Athens, Greece
Methods
An observational Consecutive Case Series; 100 consecutive myopic and myopic astigmatic SMILE-pro treatments. All cases were treated with SMILE-pro with Zeiss VISUMAX-800. Visual Acuity, Refractive Error, Scheimpflug and OCT Tomography, were evaluated over a three-month follow-up.
Results
The femto-lenticule preparation was under 8 seconds in all cases compared to the minimum 25 seconds with the older version of the Visumax 500, that we had published extensively. At the three-month follow-up, all eyes reached UDVA of 20/20 or more, change from pre- to post- operative mean values were: refractive error from -4.34D (range -7.25 to -2.00D) to -0.35 D; refractive astigmatism from -0.75 D (range 0 to -3.25D) to -0.44 D, mean topographic astigmatism from -1.28D (range -4.1 to -0.7D) to -0.88D. Defocus equivalent of 0.55 D
Conclusion
We report safe and efficient initial outcomes in Greece using SMILE-pro for myopic treatments. This technique carries the comparable outcomes and advantages with standard myopic femto LASIK without the potential short and long term disadvantages of a stromal flap.